Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)

Journal of Clinical Microbiology

Volumn 43, Issue 5, 2005, Pages 2163-2167

  Pfaller, M A ^a,b   Messer, S A ^a   Boyken, L ^a   Rice, C ^a   Tendolkar, S ^a   Hollis, R J ^a   Doern, G V ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

AFRICA; ANTIBIOTIC SENSITIVITY; ARTICLE; BROTH MICRODILUTION; CLINICAL LABORATORY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DILUTION; EUROPE; FUNGUS ISOLATION; GEOGRAPHIC DISTRIBUTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PACIFIC ISLANDS; PRIORITY JOURNAL; SOUTH AMERICA; UNIVERSITY;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; GEOGRAPHY; HUMANS; MICROBIAL SENSITIVITY TESTS;

FILOBASIDIELLA NEOFORMANS;

EID: 18544384549     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.5.2163-2167.2005     Document Type: Article

References (48)

1. Aller, A. I., E. Martin-Mazuelos, F. Lozano, J. Gomez-Mateos, L. Steele-Moore, W. J. Holloway, M. J. Gutierrez, F. J. Recio, and A. Espinel-Ingroff. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob. Agents Chemother. 44:1544-1548.
2. Alves, S. H., L. T. Oliveira, J. M. Costa, I. Lubeck, A. K. Casali, and M. H. Vainstein. 2001. In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in southern of Brazil. Rev. Inst. Med. Trop. S. Paulo 43:267-270.
3. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
4. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:1193-1199.
5. Andes, D., K. Marcillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
6. Archibald, L. K., M. J. Tuohy, D. A. Wilson, O. Nwanyanwu, P. N. Kazembe, S. Tansuphasawadikul, B. Eampokalap, A. Chaovavanich, L. B. Reller, W. R. Jarvis, G. S. Hall, and G. W. Procop. 2004. Antifungal susceptibilities of Cryptococcus neoformans. Emerg. Infect. Dis. 10:143-145.
7. Armengou, A., C. Pocar, J. Mascaro, and F. Garcia-Bragado. 1996. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 23:1337-1338.
8. Berg, J., C. J. Clancy, and M. H. Nguyen. 1998. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin. Infect. Dis. 26:186-187.
9. Birley, H. D., E. M. Johnson, P. McDonald, C. Parry, P. B. Carey, and D. W. Warnock. 1995. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int. J. STD AIDS 6:353-355.
10. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, E. A. Graviss, J. Rees, E. D. Spitzer, R. W. Pinner, L. W. Mayer, and the Cryptococcal Disease Active Surveillance Group. 1996. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in HIV-associated cryptococcosis. J. Infect. Dis. 174:812-820.
11. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, R. H. Hamill, P. G. Pappas, A. L. Reingold, D. Rimland, and D. W. Warnock for the Cryptococcal Disease Active Surveillance Group. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069.
12. Chandenier, J., K. D. Adou-Bryn, C. Douchet, B. Sar, M. Kombila, D. Swinne, M. Therizol-Ferley, Y. Buisson, and D. Richard-Lenoble. 2004. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur. J. Clin. Microbiol. Infect. Dis. 23:506-508.
13. Chang, W.-N., C.-R. Huang, C.-B. Lei, P.-Y. Lee, C.-C. Chien, H.-W. Chang, C.-S. Chang, and C.-H. Lu. 2004. Serotypes of cerebrospinal fluid Cryptococcus neoformans isolates from Southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole. Jpn. J. Infect. Dis. 57:115-117.
14. Cuenca-Estrella, M., T. M. Diaz-Guerra, E. Mellado, and J. L. Rodriguez-Tudela. 2001. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur. J. Clin. Microbiol. Infect. Dis. 20:276-279.
15. Currie, B. P., M. Ghannoum, L. Bessen, and A. Casadevall. 1995. Decreased fluconazole susceptibility of a relapse Cryptococcus neoformans isolate after fluconazole treatment. Infect. Dis. Clin. Pract. 4:318-319.
16. Datta, K., N. Jain, S. Sethi, A. Rattan, A. Casadevall, and U. Banerjee. 2003. Fluconazole and itraconazole susceptibilities of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J. Antimicrob. Chemother. 52:683-686.
17. Davey, K. G., E. M. Johnson, A. D. Holmes, A. Szekely, and D. W. Warnock. 1998. In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. J. Antimicrob. Chemother. 42:217-220.
18. de FL Fernandes, O., X. S. Passos, L. K. H. Souza, A. T. B. Miranda, C. H. P. V. Cerqueira, and M. do Rosario R. Silva. 2003. In vitro susceptibility characteristics of Cryptococcus neoformans varieties from ATDS patients in Goiania, Brazil. Mem. Inst. Oswaldo Cruz 98:839-841.
19. Groll, A. H., and H. Kolve. 2004. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur. J. Clin. Microbiol. Infect. Dis. 23:256-270.
20. Hajjeh, R. A., M. E. Brandt, and R. W. Pinner. 1995. Emergence of Cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol. Rev. 17:303-320.
21. Hajjeh, R. A., L. A. Conn, D. S. Stephens, W. Baughman, R. Hamill, E. Graviss, P. G. Pappas, C. Thomas, A. Reingold, G. Rothrock, L. C. Hutwagner, A. Schuchat, M. E. Brandt, R. W. Pinner, and the Cryptococcal Active Surveillance Group. 1999. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J. Infect. Dis. 179:449-454.
22. Hazen, K. C., and S. A. Howell. 2003. Candida, Cryptococcus, and other yeasts of medical importance, p. 1693-1711. In P. R. Murray. E. J. Baron. J. H. Jorgensen, M. A. Pfaller. and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington. D.C.
23. Husain, S., M. M. Wagener, and N. Singh. 2001. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7:375-381.
24. Kantarcioglu, A. S., and A. Yucel. 2002. A flucytosine-resistant Cryptococcus neoformans (serotype D) strain isolated in Turkey from cutaneous lesions. Med. Mycol. 40:519-523.
25. Klepser, M. E., and M. A. Pfaller. 1998. Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a University-affiliated teaching hospital from 1987 to 1994. J. Clin. Microbiol. 36:3653-3656.
26. Lozano-Chiu, M., V. L. Paetznick, M. A. Ghannoum, and J. H. Rex. 1998. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J. Clin. Microbiol. 36:2817-2822.
27. Martins, M. D., M. Lozano-Chiu, and J. J. Rex. 1998. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans. Clin. Infect. Dis. 27:1291-1294.
28. Mellinghoff, I. K., D. J. Winston, G. Mukwaya, and G. J. Schiller. 2002. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis. 34:1648-1650.
29. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
30. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution testing of yeasts. Approved standard. 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards. Wayne, Pa.
31. Nesky, M. A., C. McDougal, and J. E. Peacock, Jr. 2002. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriosis. Clin. Infect. Dis. 31:673-677.
32. Nguyen, M. H., and C. Y. Yu. 1998. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob. Agents Chemother. 42:471-472.
33. Pappas, P. G., J. R. Perfect, G. A. Cloud, R. A. Larsen, G. A. Pankey, D. J. Lancaster, H. Henderson, C. A. Kauffman, D. W. Haas, M. Saccenti, R. J. Hamill, M. S. Holloway, R. M. Warren, and W. E. Dismukes. 2001. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33:690-699.
34. Paugam, A., J. Camet-Dupouy, P. Blanche, J. P. Gangneux, C. Tourte-Schaefer, and D. Sicard. 1994. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin. Infect. Dis. 19:975-976.
35. Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nubling, H. T. Schlammn, I. Lutsor, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
36. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, S. Piscitelli, M. Candelario, A. Field-Ridley, N. Avila, J. Bacher, and T. J. Walsh. 2001. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. 45:857-869.
37. Pfaller, M. A., J. Zhang, S. A. Messer, M. E. Brandt, R. A. Hajjeh, C. J. Jessup, M. Tumberland, E. K. Mbidde, and M. A. Ghannoum. 1999. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43:169-171.
38. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal program. Diagn. Microbiol. Infect. Dis. 48:201-205.
39. Pfaller, M. A., and D. J. Diekema. 2002. The role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40:3551-3557.
40. Pfaller, M. A., and D. J. Diekema. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(suppl. 1):11-23.
41. Poonwan, N., Y. Mikami, S. Poosuwan, J. Boon-Long, N. Mekha, M. Kusum, K. Yazawa, R. Tanaka, K. Nishimura, and K. Konyama. 1997. Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents. Eur. J. Epidemiol. 13:335-340.
42. Powderly, W. G., E. J. Keath, M. Sokol-Anderson, K. Robinson, D. Kirtz, J. R. Little, and G. Kobayashi. 1992. Amphotericin B-resistant Cryptococcus neoformans in a patient with AIDS. Infect. Dis. Clin. Pract. 1:314-316.
43. Saag, M. S., R. J. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G. Powderly, J. D. Sobel, W. E. Dismukes, et al. 2000. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30:710-718.
44. Sar, B., D. Monchy, M. Vann, C. Keo, J. L. Sarthou, and Y. Buisson. 2004. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J. Antimicrob. Chemother. 54:563-565.
45. Schwartz, S., D. Milatovic, and E. Thiel. 1997. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br. J. Haematol. 97:663-665.
46. Tattevin, P., F. Bruneel, F. Lellouche, T. de Broucker, S. Chevret, M. Wolff, and B. Regnier. 2004. Successful treatment of brain aspergillosis with voriconazole. Clin. Microbiol. Infect. 10:928-930.
47. Yamazumi, T., M. A. Pfaller, S. A. Messer, A. Houston, R. J. Hollis, and R. N. Jones. 2000. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:2883-2886.
48. Yildiran, S. T., A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. 2002. In vitro susceptibility of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 45:378-383.